Stocksigma LogoStocksigma Logo

Gland Pharma Dundigal Facility Receives Four USFDA Form 483 Observations

The USFDA concluded an unannounced cGMP inspection at Gland Pharma Limited鈥檚 Dundigal formulation facility, conducted from 12th Oct'26 to 23rd Oct'26

Gland Pharma Dundigal Facility Receives Four USFDA Form 483 Observations

Gland Pharma Ltd 路 Others (Uncategorized) 路 23 Oct 2026, 9:51 pm

Gland Pharma Dundigal Facility Receives Four USFDA Form 483 Observations The USFDA concluded an unannounced cGMP inspection at Gland Pharma Limited鈥檚 Dundigal formulation facility, conducted from 12th Oct'26 to 23rd Oct'26, issuing Form 483 with four observations. The company confirmed that all observations are procedural in nature, are neither repeated nor related to data integrity, and have no quantifiable impact on financials or operations. Corrective and preventive actions (CAPA) will be submitted to the regulator within the stipulated timeline.

Original exchange filing (PDF)

More announcements from Gland Pharma Ltd

All Gland Pharma Ltd announcements